A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

NCT07348861 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Sacituzumab tirumotecan plus Iparomlimab

Sponsor

Zheng Min

Collaborators

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.